News

Big names from pharma, Google, Dreamworks join cognitive therapy company Akili

June 29, 2017

All will work on the development of Akili’s gaming therapy portfolio.

Big names from pharma, Google, Dreamworks join cognitive therapy company Akili

https://pharmaphorum.com/news/cubist-google-dreamworks-akili/

As Mystic unveiling nears, AZ keeps cancer options open with Chi-Med

June 29, 2017

First ever targeted agent in renal cell carcinoma could be strong addition to AZ oncology portfolio

As Mystic unveiling nears, AZ keeps cancer options open with Chi-Med

https://pharmaphorum.com/news/mystic-unveiling-nears-az-keeps-cancer-options-open-chi-med/

Millions will be affected by STP health service cuts, say doctors

June 28, 2017

BMA figures show cost of introducing STPs

Millions will be affected by STP health service cuts, say doctors

https://pharmaphorum.com/news/millions-affected-nhs-cuts-doctors/

NICE recommends Sanofi’s Gaucher treatment

June 28, 2017

Cancer drugs from Novartis and Pfizer also backed

NICE recommends Sanofi’s Gaucher treatment

https://pharmaphorum.com/news/nice-recommends-sanofis-gaucher-treatment/

Alder shares slump despite migraine success

June 28, 2017

Investors concerned over strong placebo effect

Alder shares slump despite migraine success

https://pharmaphorum.com/news/alder-shares-slump-despite-migraine-success/

Stroke prevention device wins healthtech award

June 28, 2017

Neuravi’s Embotrap II can clear blood clots responsible for stroke.

Stroke prevention device wins healthtech award

https://pharmaphorum.com/news/neuravi-digital-health-award/

Merck & Co hit by GoldenEye ransomware

June 28, 2017

Attack overshadows surprise success for cholesterol drug

Merck & Co hit by GoldenEye ransomware

https://pharmaphorum.com/news/merck-co-hit-goldeneye-virus/

Kisqali set for approval – but likely to hit same NICE obstacles as rival

June 28, 2017

Concerns that NICE will reject Kisqali like it did Ibrance.

Kisqali set for approval – but likely to hit same NICE obstacles as rival

https://pharmaphorum.com/news/will-patients-access-novartis-breast-cancer-drug-england/

More good news for Bluebird Bio with CALD gene therapy

June 27, 2017

Bluebird Bio has presented encouraging data from its gene therapy treatment for the rare condition, cerebral adrenoleukodystrophy (CALD). The

More good news for Bluebird Bio with CALD gene therapy

https://pharmaphorum.com/news/good-news-bluebird-bio-cald-gene-therapy/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

News

News

As Mystic unveiling nears, AZ keeps cancer options open with Chi-Med

Millions will be affected by STP health service cuts, say doctors

NICE recommends Sanofi’s Gaucher treatment

Alder shares slump despite migraine success

Merck & Co hit by GoldenEye ransomware

Kisqali set for approval – but likely to hit same NICE obstacles as rival

More good news for Bluebird Bio with CALD gene therapy

2nd Annual Cancer Immunotherapy Summit

AI Pharma Innovation Summit

7th Annual Partnership Opportunities in Drug Delivery (PODD)

Big names from pharma, Google, Dreamworks join cognitive therapy company Akili

As Mystic unveiling nears, AZ keeps cancer options open with Chi-Med

Millions will be affected by STP health service cuts, say doctors

NICE recommends Sanofi’s Gaucher treatment

Alder shares slump despite migraine success

A digital NHS needs to come quicker – but funding is still elusive

Five tech companies advancing against cancer

The home advantage in cancer care

Digital health round-up: Nokia’s rebirth

Will UK patients get access to novel drugs?

Search

Advanced Search

Trending

News

News